Physician profile
Aswin Mathew
NPI 1447547104
$15,814.23
in general payments reported to CMS, 2019-2025
33 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,042 · 2020: $533 · 2021: $1,591 · 2022: $3,605 · 2023: $2,327 · 2024: $1,282 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,043.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $3,022.71 | 2019-2025 | Impella |
| Csl Behring | $2,583.13 | 2019 | |
| Boston Scientific Corporation | $2,499.77 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Emblem Mri S-Icd |
| Terumo Medical Corporation | $1,384.35 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $904.41 | 2021-2023 | Optimizer |
| Amgen INC. | $613.92 | 2021-2025 | Repatha |
| Medtronic, INC. | $598.58 | 2022-2025 | Symplicity G3, Onyx Frontier, Selectsecure |
| Novartis Pharmaceuticals Corporation | $498.91 | 2021-2025 | |
| Abbott Laboratories | $494.03 | 2020-2025 | Xience Sierra, Mitraclip, Esprit |
| Shockwave Medical, INC | $361.74 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $341.78 | 2021-2024 | Xarelto |
| Bard Peripheral Vascular, INC. | $297.15 | 2019-2021 | |
| Philips North America LLC | $294.76 | 2019-2022 | |
| Esperion Therapeutics, INC. | $268.25 | 2022-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $219.01 | 2021-2025 | Farxiga, Lokelma |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $188.28 | 2019 | |
| Corindus INC. | $148.78 | 2019 | |
| Penumbra, INC. | $147.30 | 2023 | Indigo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.31 | 2021-2025 | Lifevest |
| Pfizer INC. | $129.17 | 2022-2025 | |
| Edwards Lifesciences Corporation | $115.15 | 2019 | |
| Biotronik INC. | $99.42 | 2022 | |
| Merck Sharp & Dohme LLC | $83.63 | 2021-2025 | Verquvo, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $56.70 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $52.40 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $52.03 | 2024 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $47.41 | 2021-2022 | |
| Angiodynamics, INC. | $43.83 | 2024-2025 | Angiovac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.38 | 2022-2023 | Jardiance |
| Novo Nordisk INC | $34.28 | 2021-2022 | |
| Cardiovascular Systems INC. | $23.22 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $20.97 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $14.47 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aswin Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.